

## Anticipated First Time Generics 2008 - 2011

Brand Name	Common Uses	Manufacturer	2007 U.S. Retail Sales (millions)	Anticipated Availability*	
				Period	Year
Casodex®	Prostate Cancer	AstraZeneca	\$207	4th Quarter	2008
Trusopt®	Glaucoma	Merck	\$140	4th Quarter	2008
Glyset®	Diabetes	Pfizer	\$7	1st Quarter	2009
Imitrex®	Migraine Headache	GlaxoSmithKline	\$1,071	1st Quarter	2009
Lamictal®	Seizures	GlaxoSmithKline	\$1,717	1st Quarter	2009
Prandin®	Diabetes	Novo Nordisk	\$131	1st Quarter	2009
Zerit®	Antiviral	Bristol-Myers Squibb	\$51	1st Quarter	2009
Ambien CR®	Insomnia	Sanofi Aventis	\$876	2nd Quarter	2009
Topamax®	Seizures	Ortho-McNeil	\$1,837	2nd Quarter	2009
Aceon®	Hypertension	Solvay	\$28	4th Quarter	2009
Acular®	Ophthalmic Antiinflammatory	Allergan	\$37	4th Quarter	2009
Flomax®	Benign Prostatic Hyperplasia	Boehringer Ingelheim	\$1,002	4th Quarter	2009
Prevacid®	GERD / Ulcer	Abbott	\$3,316	4th Quarter	2009
Valtrex®	Antiviral	GlaxoSmithKline	\$1,395	4th Quarter	2009
Keppra®	Seizures	UCB	\$708	1st Quarter	2010
Teveten® & Teveten® HCT	Hypertension	KOS	\$21	1st Quarter	2010
Differin®	Acne	Galderma	\$188	2nd Quarter	2010
Cardene® SR	Hypertension	Roche	\$2	2nd Quarter	2010
Cozaar®	Hypertension	Merck	\$652	2nd Quarter	2010
Hyzaar®	Hypertension	Merck	\$500	2nd Quarter	2010
Arimidex®	Cancer	AstraZeneca	\$506	3rd Quarter	2010
Aricept®	Alzheimers Disease	Eisai	\$983	4th Quarter	2010
Actos®	Diabetes	Takeda	\$2,229	1st Quarter	2011
Aldara®	Skin Disorders	Graceway Pharmaceuticals	\$287	1st Quarter	2011
Astelin®	Hay Fever	MedPointe Healthcare	\$219	2nd Quarter	2011
Cosopt®	Glaucoma	Merck	\$242	2nd Quarter	2011
Xalatan®	Glaucoma	Pfizer	\$431	2nd Quarter	2011
Effexor® XR	Depression, Anxiety	Wyeth	\$2,464	3rd Quarter	2011
Femara®	Breast Cancer	Novartis	\$293	3rd Quarter	2011
Lipitor®	High Cholesterol	Pfizer	\$6,165	3rd Quarter	2011
Levaquin®	Antibiotic	Ortho-McNeil	\$1,433	3rd Quarter	2011
Seroquel®	Schizophrenia	AstraZeneca	\$2,518	4th Quarter	2011
Tazorac®	Acne, Psoriasis	Allergan	\$111	4th Quarter	2011
Zyprexa®	Schizophrenia	Eli Lilly	\$1,579	4th Quarter	2011

\* Anticipated availability is subject to change as a result of litigation, pediatric or other exclusivities.

**Sources:**

FDA, Approved Drug Products with Therapeutic Equivalence Evaluations (Electronic Orange Book)  
Drug Topics, Top 200 Brand-Name Drugs by Retail Dollars in 2007

Last Updated August 2008

[www.theunadvertisedbrand.com](http://www.theunadvertisedbrand.com)



the **un**advertised brand